Australian research into the use of convalescent plasma in clinical trials for the prevention and treatment of COVID-19 should be supported according to a leading immunologist.
Strep A, which can lead to serious illness and death if untreated, should be recognised as a Neglected Tropical Disease according to a leading infectious disease expert. Professor Michael Good AO, Principal Research Leader at Griffith University’s Institute for Glycomics, authored a paper published this week in PLOS Neglected Tropical Diseases. Neglected tropical diseases (NTDs) […]
Lives are at risk due to ceasing research on diseases that in addition to COVID-19 have a major impact on public health warn scientists.
Four teams of expert scientists from Griffith University’s Institute for Glycomics are targeting the virus SARS-CoV-2 to discover new vaccines and drugs to prevent or cure COVID-19. The teams are led by the Institute’s group leaders Professor Mark von Itzstein AO, Professor Michael Good AO, Professor Michael Jennings, and Professor Johnson Mak, all world-renowned research […]
A new vaccine developed by Griffith University Institute for Glycomics researchers has the potential to treat and prevent toxic shock caused by invasive streptococcal disease, which kills more than 160,000 people every year. “Streptococcal toxic shock syndrome is an acute condition like meningococcus – if you get exposed to the organism you can be dead […]
When Professor Michael Good first arrived at Griffith University seven years ago he never imagined that a vaccine to protect against the nasty Streptococcus A infection would already be at pharmaceutical development stage. But with the support of Vice Chancellor Ian O’Connor, Institute for Glycomics Director Professor Mark von Itzstein and a remarkable research team […]